Display options
Cite
Guillin O. Les antipsychotiques de la future décade. [What antipsychotic drugs will be in the next decade?]. Bull Acad Natl Med. 2020;204(9):1043-1046doi: 10.1016/j.banm.2020.10.005.
Guillin, O. (2020). Les antipsychotiques de la future décade. [What antipsychotic drugs will be in the next decade?]. Bulletin de l'Academie nationale de medecine, 204(9), 1043-1046. https://doi.org/10.1016/j.banm.2020.10.005
Guillin, O. "Les antipsychotiques de la future décade." [What antipsychotic drugs will be in the next decade?]. Bulletin de l'Academie nationale de medecine vol. 204,9 (2020): 1043-1046. doi: https://doi.org/10.1016/j.banm.2020.10.005
Guillin O. Les antipsychotiques de la future décade. [What antipsychotic drugs will be in the next decade?]. Bull Acad Natl Med. 2020 Dec;204(9):1043-1046. doi: 10.1016/j.banm.2020.10.005. Epub 2020 Oct 13. French. PMID: 33071288; PMCID: PMC7553002.
Copy Download .nbib Format: NLM
Share it on

Bull Acad Natl Med. 2020 Dec;204(9):1043-1046. doi: 10.1016/j.banm.2020.10.005. Epub 2020 Oct 13.

[What antipsychotic drugs will be in the next decade?].

Bulletin de l'Academie nationale de medecine

[Article in French]
O Guillin

Affiliations

  1. CHU de Rouen, centre hospitalier du Rouvray, université de Normandie, Inserm U1245, 4, rue Paul-Eluard, 76300 Sotteville-lès-Rouen, France.

PMID: 33071288 PMCID: PMC7553002 DOI: 10.1016/j.banm.2020.10.005

Abstract

Antipsychotic drugs are one of the oldest drugs that can change the brain activity. These drugs are mainly used in schizophrenia and the first drug that was judged as efficacious in the treatment of psychosis has been chlorpromazine. This is a decade later that it has been shown that these drugs were antagonists at the dopamine transmission by blocking the dopamine D2/D3 receptors. Several other pharmacological targets have been tested during the last decades as glutamatergic, serotoninergic, cholinergic and neuropeptidergic agents but none has been shown to improve symptoms of schizophrenia. Three main issues could explain this failure: the exact causes of schizophrenia is still unknown, we still used the idea that one drug could improve all the symptoms of schizophrenia and it is clear that the group of schizophrenics disease could be different disease with different causes. We propose to review the different drugs that have been tested and we will discuss why the most recent genetic studies could help us to propose new pharmacological targets to treat schizophrenia.

© 2020 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine.

Keywords: Antipsychotic drugs; Dopamine; Genetic; Schizophrenia

References

  1. Drugs Today (Barc). 2018 Dec;54(12):713-719 - PubMed
  2. Biol Psychiatry. 2015 Dec 1;78(11):754-62 - PubMed
  3. Trends Neurosci. 1990 Jul;13(7):272-6 - PubMed
  4. Nature. 2014 Feb 13;506(7487):185-90 - PubMed
  5. Lancet. 2013 Sep 14;382(9896):951-62 - PubMed
  6. Ann Med Psychol (Paris). 1952 Jun;110(2 1):112-7 - PubMed
  7. Acta Pharmacol Toxicol (Copenh). 1963;20:140-4 - PubMed
  8. Neuropsychopharmacology. 2019 Oct;44(11):1917-1924 - PubMed
  9. JAMA Psychiatry. 2018 Dec 1;75(12):1261-1269 - PubMed
  10. J Psychiatr Res. 2019 Jan;108:57-83 - PubMed
  11. Psychopharmacology (Berl). 2020 Jan;237(1):231-248 - PubMed

Publication Types